Taxanes in adjuvant breast cancer setting: Which standard in Europe?

Critical Reviews in Oncology/Hematology

Volumn 55, Issue 3, 2005, Pages 167-175

  Campone, Mario ^a   Fumoleau, Pierre ^b   Bourbouloux, Emmanuelle ^a   Kerbrat, Pierre ^c   Roché, Henri ^d  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

^c CENTRE EUGÈNE MARQUIS   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Adjuvant therapy; Breast cancer; Review; Taxanes

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE;

ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DOSE RESPONSE; EUROPE; FEBRILE NEUTROPENIA; HUMAN; NEUTROPENIA; PARESTHESIA; SENSORY NEUROPATHY; THROMBOCYTOPENIA;

EID: 24044511109     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2005.04.003     Document Type: Review

References (27)

1. G. Bonadonna, and P. Valagussa Dose-response effect of adjuvant chemotherapy in breast cancer N Engl J Med 304 1 1981 10 15
2. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group Lancet 339 8784 1992 1 15
3. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group Lancet 352 9132 1998 930-42
4. Adjuvant Therapy for Beast Cancer. NIH Consensus Statement 2000 November 1-3;17(4):23, http://odp.od.nih.goc/consensus/cons/114/114_statement.htm.
5. C. Henderson, D.A. Berry, and G.D. Demetri Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 2003 976 983
6. E.P. Mamounas, J. Bryant, and B.C. Lembersky Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSA B-28 Proc Am Soc Clin Oncol 22 2003 A12
7. A.U. Buzdar, S.E. Singletary, and V. Valero Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial Clin Cancer Res 8 2002 1073 1079
8. M.L. Citron, D.A. Berry, and C. Cirrincione Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 21 2003 1431 1439
9. M. Martin, T. Pienkowski, and J. Mackey TAC improves DFS and OS over FAC in node positive eraly breast cancer patients, BCRIG 001 Breast Cancer Res Treat 82 Suppl. 1 2003 43
10. H. Roché, P. Fumoleau, and M. Spielman Five years analysis of the PAC01 trial: 6 cycles of FEC 100 versus 3 cycles of FEC 100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer Breast Cancer Res Treat 88 Suppl. 1 2004 A27
11. C. Pico, M. Martin, and C. Jara Epirubicin-cyclophsphamide adjuvant chemotherapy plus tamoxifen admnistreted concurrently versus suquentially: randomized phase III trial in postmenopausal node-positive beast cancer patients. A GEICAM 9401 study Ann Oncol 15 2004 79 87
12. K. Albain, W. Barlow, and F. O'alley Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorobubicin, 5-fluorouracil, tamoxifene) versus T alone for postmenauposal, node positive, estrogene (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup 0100 (SWOG-8814). Breast Cancer Res Treat 88 Suppl. 1 2004 A37
13. P. Fumoleau, P. Kerebrat, and P. Romestaing Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node positive breast cancer patients: 10 years follow-up results of the French Adjuvant Study Group 01 trial J Clin Oncol 21 2003 298 305
14. E. Perez Adjuvant chemotherapy: contreversies and the role of taxanes Breast J 9 2003 S25 S28
15. B. Fisher, A.M. Brown, and N.V. Dimitrov Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15 J Clin Oncol 8 1990 1483 1496
16. M.N. Levine, V.H. Bramwell, and K.I. Pritchard Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 1 1998 2651 2658
17. C.J. Poole, H.M. Earl, and J.A. Dunn NEAT (National Epirubicin Adjuvant trial) and SCTBG BR 9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF Proc Am Soc Clin Oncol 22 2003 A13
18. French Adjuvant Study Group Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5 years follow-up results of French Adjuvant Study Group 05 Randomized trial J Clin Oncol 19 2001 602 611
19. M.J. Piccart, A. Di Leo, and M. Beauduin Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer J Clin Oncol 15 2001 3103 3110
20. French Epirubicin Study Group A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin J Clin Oncol 6 1988 679 688
21. P. Fumoleau, J. Bonneterre, and E. Luporsi Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today? J Clin Oncol 6 2003 1190 1191 (author reply 1191-2)
22. R. Buzzoni, G. Bonadonna, and P. Valagussa Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes J Clin Oncol 9 1991 2134 2140
23. G. Bonadonna, M. Zambetti, and A. Moliterni Clinical revelance of different sequencing of doxorubicin and cyclophosphamide, methotrexate and fluorouracil in operable breast cancer J Clin Oncol 22 2004 1614 1620
24. M. Perloff, L. Norton, and A.H. Korzun Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study J Clin Oncol 14 1996 1589 1598
25. L. Norton Adjuvant breast cancer therapy: current status and future strategies - growth kinetics and the improved drug therapy of breast cancer Semin Oncol 26 1 Suppl. 3 1999 1 4
26. A.D. Seidman, D. Berry, and C. Cirrincione CALGB 9840: phase III study of weekly (W) paclitaxel (P) via-1 h (h) infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC) with trastuzumab (T) for HER2 positive MBC and randomised for T in HER2 normal MBC Proc Am Soc Clin Oncol 23 2004 512
27. M.C. Green, A.U. Buzdar, and T. Smith Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q 3 wk) P therapy (tx) followed by FAC final results of a prospective phase III randomized trial Proc Am Soc Clin Oncol 21 2002 A135